Arthur Allen of Kaiser Health News

Image

FRITZ LIEDTKE/OREGON HEALTH & SCIENCE UNIVERSITY

How Pfizer Won The Pandemic, Reaping Outsize Profit And Influence

Pfizer's success in developing COVID medicines has given the drugmaker unusual weight in determining U.S. health policy.

Jul 5, 2022

Image

DONA TEMPEST/KHN

Why Cheap, Older Drugs That Might Treat COVID Never Get Out Of The Lab

A few older drugs show promise as COVID-fighters, but some scientists say the pharmaceutical industry has shown little interest in testing them when it can earn billions from mediocre new ones.

Apr 19, 2022

Image

JÁNOS KOROM/WIKIMEDIA COMMONS

Pfizer CEO Pushes Yearly Shots For COVID. Not So Fast, Experts Say.

When Albert Bourla said all Americans will need a second booster shot, some experts saw his claim as self-serving.

Mar 22, 2022

Image

An epic tug of war is playing out behind the scenes over whether the government should pay for Aduhelm, a controversial Alzheimer’s drug that scientists say has not been proven to work./Lydia Zuraw/KHN

Inside The Tactical Tug Of War Over The Controversial Alzheimer’s Drug

Pharmaceutical industry and patients representatives want to stop restricting Medicare funding for a controversial Alzheimer’s drug. Critics say it should never have been approved.

Feb 17, 2022